Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission
Results from the Iceberg study
Datos Bibliográficos
| ID | 15519281 |
|---|---|
| Autores | Albino J Oliveira-Maia (0000-0001-5071-3007, Champalimaud Foundation), Benoît Rive (Janssen (France), autor de correspondencia), Yordan Godinov, Siobhán Mulhern-Haughey (0000-0002-9708-4356, Janssen (Ireland)) |
| Año | 2024 |
| Volumen | 15 |
| Páginas | 1459633-1459633 |
| Fecha de publicación | 2024-10-07 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Frontiers in Psychiatry (JOURNAL) |
| Identificadores de la revista | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Editorial | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2024.1459633 |
| PMID | 39435126 |
| OpenAlex | W4403199683 |
| Idioma | EN |
| Referencias citadas | 4 |
For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery
Anesthesia · Iceberg · Nasal administration · Nasal spray · Ginkgo biloba and Cashew Applications · Medicine · Olfactory and Sensory Function Studies · Treatment of Major Depression · Geology · Pharmacology
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |